The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Drugs for exceptionally rare diseases: do they deserve special status for funding?
Abstract
Ultra-orphan drugs are medicines used to treat exceptionally rare diseases that are chronically debilitating or life-threatening. Low patient numbers make it difficult for pharmaceutical companies to recoup research and development costs, and consequently these medicines are generally expensive on a per patient basis. European Union (EU) regulations promote the development of orphan drugs; but to contain costs, some EU healthcare systems assess the cost-effectiveness of therapies when deciding if they should be funded. As ultra-orphan drugs are invariably cost-ineffective, factors in addition to cost-effectiveness need to be considered if ultra-orphan drugs are to be provided by public health services. Health service funding of ultra-orphan drugs, which varies across the EU and within the UK, has led to geographical inequities in patients' access to treatment. In some instances, support for these drugs would appear to have been approved on the basis that diseases that are rare and severe are a special case. We explore whether ultra-orphan drugs merit special status by considering efficiency, effectiveness and equity criteria. Mechanisms are discussed for creating a policy that would reduce geographical inequalities in provision across Europe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care
Chapman, S., Reeve, E., Rajaratnam, G., & Neary, R. (2003) · BMJ · doi:10.1136/bmj.326.7391.707 · Cited by 44
Cited by
Pricing and reimbursement of orphan drugs: the need for more transparency
Simoens, S. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-42 · Cited by 260
A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
Rathbone, J., Kaltenthaler, E., Richards, A., Tappenden, P., Bessey, A., & Cantrell, A. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003573 · Cited by 110
Protein replacement therapies for rare diseases: a breeze for regulatory approval?
Gorzelany, J. A., & de Souza, M. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005007 · Cited by 33
Metadata
- Authors
- Hughes, D. A., Tunnage, B., & Yeo, S. T.
- Venue
- QJM: An International Journal of Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-10-03
- Volume
- 98
- Issue
- 11
- Pages
- 829-836
- ISSN
- 0033-5622 (ISSN-L)
- 1460-2393
- 1460-2725
- OpenAlex
- W2105845113
- Cited by
- 219
- References
- 1
- FWCI
- 18.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drugs for exceptionally rare diseases: do they deserve special status for funding? https://app.cochat.ai/papers/10.1093/qjmed/hci128
- The paper
- Hughes, D. A., Tunnage, B., & Yeo, S. T. (2005). Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hci128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.